Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urine dipstick

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    368 result(s) found for: Urine dipstick. Displaying page 1 of 19.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-003894-18 Sponsor Protocol Number: M07CCL Start Date*: 2008-01-30
    Sponsor Name:NKI-AVL
    Full Title: Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma
    Medical condition: Non-small cell lung cancer locally advanced
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004824-19 Sponsor Protocol Number: ML21206 Start Date*: 2008-08-08
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study
    Medical condition: Chronic Lymphocytic Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002902-20 Sponsor Protocol Number: ML21901 Start Date*: 2008-10-15
    Sponsor Name:Onkološki inštitut Ljubljana
    Full Title: Preoperative Radiotherapy with Capecitabine and Bevacizumab in locally advanced rectal cancer: CRAB Phase II study
    Medical condition: Locally advanced rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender:
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006161-13 Sponsor Protocol Number: ML19983 Start Date*: 2007-06-22
    Sponsor Name:Roche Pharma AG
    Full Title: A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta...
    Medical condition: Metastatic renal cell cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005887-97 Sponsor Protocol Number: MO19390 Start Date*: 2006-07-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer
    Medical condition: Advanced or recurrent non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9 10059515 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) ES (Completed) NL (Completed) AT (Completed) CZ (Completed) EE (Completed) DE (Completed) LT (Completed) HU (Completed) SK (Completed) GB (Completed) PT (Completed) DK (Completed) LV (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001443-39 Sponsor Protocol Number: 167700-004CL Start Date*: 2016-09-23
    Sponsor Name:Proximagen Ltd.
    Full Title: A Randomised, Parallel Arm, Placebo-Controlled, Double-Blind, Study of the Safety and Efficacy of PRX167700 Added to Existing Non-steroidal Anti-inflammatory Therapy in Adults with Moderate-to-Seve...
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000026-31 Sponsor Protocol Number: ML18704 Start Date*: 2006-06-20
    Sponsor Name:Roche Austria GmbH
    Full Title: Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma
    Medical condition: Multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002886-11 Sponsor Protocol Number: BEBYP Start Date*: 2008-01-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLU...
    Medical condition: METASTATIC COLORECTAL CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006051-40 Sponsor Protocol Number: Beva2007 Start Date*: 2008-09-09
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: A PHASE II STUDY: UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER METRONOMIC BIOCHEMOTHERAPY WITH WEEKLY CISPLATIN, DAILY ORAL ETOPOSIDE AND BEVACIZUMAB (mPEBev regimen)
    Medical condition: Patients with UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001160 Adenocarcinoma lung LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003006-34 Sponsor Protocol Number: ML21744 Start Date*: 2008-07-03
    Sponsor Name:Oslo Universitetssykehus
    Full Title: A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in...
    Medical condition: HER2 negative breast cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002529-21 Sponsor Protocol Number: MO19391 Start Date*: 2006-09-05
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: Open-label study of bevacizumab (Avastin®) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer
    Medical condition: Locally recurrent or metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) ES (Completed) EE (Completed) AT (Completed) CZ (Completed) DE (Completed) LT (Completed) LV (Completed) SI (Completed) HU (Completed) SE (Completed) SK (Completed) PT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002716-27 Sponsor Protocol Number: ALN-CC5-005 Start Date*: 2019-06-11
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
    Medical condition: Immunoglobulin A nephropathy (IgAN)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022520-73 Sponsor Protocol Number: CT/10.15 Start Date*: 2011-07-12
    Sponsor Name:Hellenic Oncology Research Group
    Full Title: Phase II, open-label non-randomized trial to investigate the efficacy of Bevacizumab in combination with dose dense sequential chemotherapy in the neo-adjuvant setting for HER2 negative breast canc...
    Medical condition: Early breast cancer (primary operable HER2-negative breast cancer)
    Disease:
    Population Age: Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004833-70 Sponsor Protocol Number: BUSAL-III-08-1 Start Date*: 2009-01-16
    Sponsor Name:Laboratoires SMB S.A.
    Full Title: A phase III, randomized, parallel group, open study to compare the therapeutic efficacy and safety of SMB BUDESONIDE-SALMETEROL DPI capsule 150/25μg BID delivered by the AXAHALER® versus SYMBICORT®...
    Medical condition: Patients with moderate to severe persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049106 Asthma chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-001537-10 Sponsor Protocol Number: ASL608LIOM04 Start Date*: 2008-05-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004983-30 Sponsor Protocol Number: ACO-ASSO LM1 Start Date*: 2006-11-03
    Sponsor Name:ACO-ASSO
    Full Title: Pre- and postoperative chemotherapy including Bevacizumab in potentially curable metastatic colorectal Cancer (mCRC). A multicenter, prospective Phase I/II academic trial.
    Medical condition:  Patients with histologically confirmed diagnosis of metastatic Colorectal Cancer (CRC) including potentially resectable liver metastases, untreated yet with chemotherapy for metastatic disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004748-22 Sponsor Protocol Number: ML20058 Start Date*: 2006-12-14
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocri...
    Medical condition: Patients with Advanced Inoperable Well-Differentiated Neuroendocrine Tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057270 Neuroendocrine carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011377-33 Sponsor Protocol Number: 08_CLPHA_55 Start Date*: 2009-06-25
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10056417 Monoclonal antibody unconjugated therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001517-15 Sponsor Protocol Number: ML 19309 Start Date*: 2006-10-26
    Sponsor Name:ROCHE
    Full Title: Italian multicenter phase II trial using Fotemustine plus Bevacizumab as first-line therapy in metastatic melanoma.
    Medical condition: Patients with stage IV melanoma, previously untreated with chemo- or immuno-therapy for metastatic disease, will be eligible for the study.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025671 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004429-27 Sponsor Protocol Number: ONC-2006-003 Start Date*: 2007-05-25
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma
    Medical condition: Histologically proven diagnosis of malignant pleural mesothelioma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059518 Pleural mesothelioma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 10:38:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA